Don Taylor

Executive-In-Residence (EIR)

Dr. Taylor is an experienced life sciences executive, with more than 20 years of life sciences commercial development involvement. Dr. Taylor began his career as Co-founder, President and CEO of Net Health Systems, Inc., a healthcare information technology company engaged in web-based disease state management (acquired in 2012).

Prior rejoining PLSG in 2010, he served as the Vice President of Corporate Development for Cellumen, Inc., a biotools company, and the predecessor company Cernostics, Inc., a cancer molecular diagnostics company. Prior to Cellumen and Cernostics, Don was the Global Pharmaceutical and Biotechnology Market Segment Manager for Thermo Fisher Scientific, Inc., where he led product marketing campaigns across a sales team of more than 500 people and $400 million in revenue.  Don was the Senior Director of Business Development for Vivisimo, Inc., (acquired by IBM in 2012) providing big data software to the pharmaceutical and biotech industries. Prior to Vivisimo, Don was the Vice President of Business Development for Strategic Healthcare Programs, LLC (SHP), a Frost & Sullivan award-winning healthcare information technology company.

Don represents the PLSG as Chairman of PHRQL and a board member to Hability, two leading healthcare information technology companies.  Don has also served on the board of directors of several biotechnology companies; including Sculptor Developmental Technologies that he helped sell to Hospira, Inc. in 2008. Don has been published in leading journals such as Cancer Research, Stem Cell Research and Therapy, and Topics of Health Information Technology.   Don is an Adjunct Professor of Information Systems at Carnegie Mellon University, and an Adjunct Professor of Bioengineering, Chemical Engineering, Plastic Surgery at the University of Pittsburgh’s Swanson School of Engineering, faculty at the McGowan Institute for Regenerative Medicine and adjunct professor of biomedical engineering by courtey at Duquesne University.

Don received a B.S. in Information Systems from Carnegie Mellon University, an M.S. and Ph.D. in Bioengineering from the Swanson School of Engineering at the University of Pittsburgh, an MBA from the Katz Graduate School of Business at the University of Pittsburgh, and conducted postdoctoral research at the University of Pittsburgh School of Medicine in the Department of Pathology.  Dr. Taylor’s research was in collaboration with Massachusetts Institute of Technology on computational and wet lab investigations of cancer metastasis, wound healing, and stem cell therapies.